Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the programREDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related t ...